|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.
|
30948344 |
2020 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
MRI Features Associated with TERT Promoter Mutation Status in Glioblastoma.
|
30644143 |
2019 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutation was observed in 7/17 patients with diffuse astrocytic glioma, IDH-wild type; recently-defined as "molecular GBM."
|
31639630 |
2019 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutations occur in the majority of glioblastoma, bladder cancer (BC), and other malignancies while the ETS family transcription factors GABPA and its partner GABPB1 activate the mutant TERT promoter and telomerase in these tumors.
|
31802036 |
2019 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
Eribulin inhibited the growth of 4 TERT promoter mutation-harboring glioblastoma cell lines in vitro at subnanomolar concentrations.
|
31099446 |
2019 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma.
|
30187121 |
2018 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
These results highlight the critical role of GABPβ1L in enabling immortality in TERT promoter mutant glioblastoma.
|
30205050 |
2018 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
Biomarker |
BEFREE |
TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
|
30333046 |
2018 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
PosttranslationalModification |
BEFREE |
Wild-type IDH was present in 89.8% of the adult glioblastoma samples, and TERT promoter mutations and MGMT promoter methylation were observed in 66.42% and 38.49% of all adult primary glioblastomas, respectively.
|
29984907 |
2018 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
Biomarker |
BEFREE |
Here we report the genetic landscape of TERTp<sup>WT</sup>-IDH<sup>WT</sup> glioblastoma and identify SMARCAL1 inactivating mutations as a novel genetic mechanism of ALT.
|
29802247 |
2018 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
In gliomas, the TERT promoter mutation (TPM) and resultant overexpression of TERT are observed mainly in the most aggressive (primary glioblastoma/grade IV astrocytoma) and the least aggressive (grade II oligodendroglioma) cases.
|
29525892 |
2018 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
NGS data obtained in a retrospective analysis of 121 gliomas allowed for their molecular classification into distinct biological groups, including (i) isocitrate dehydrogenase gene (IDH) 1 or 2 mutant astrocytic gliomas with frequent α-thalassemia/mental retardation syndrome X-linked (ATRX) and tumor protein p53 (TP53) gene mutations, (ii) IDH mutant oligodendroglial tumors with 1p/19q codeletion, telomerase reverse transcriptase (TERT) promoter mutation and frequent Drosophila homolog of capicua (CIC) gene mutation, as well as (iii) IDH wildtype glioblastomas with frequent TERT promoter mutation, phosphatase and tensin homolog (PTEN) mutation and/or epidermal growth factor receptor (EGFR) amplification.
|
26919320 |
2017 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
In studying its reaction with IDH, TERT promoter mutation was associated with reduced OS in both IDH-mutant (IDH-mut) and IDH-wild type (IDH-wt) glioblastomas but shown to have inverse effects on IDH-mut and IDH-wt grade II/III tumors.
|
29198322 |
2017 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, the presence of TERTp mutations was associated with worse prognosis in GBM patients, although such association depended on the status of the rs2853669 SNP.
|
26914704 |
2016 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.
|
26608520 |
2016 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.
|
27503138 |
2016 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
Voxel-based statistical analysis demonstrated that GBMs with TERT promoter mutations were much more likely to locate in the right temporal lobe, while those with wild-type TERT promoters were more likely to occur in the anterior region of the right lateral ventricle.
|
27230769 |
2016 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
We observed positive association between TERT promoter and IDH mutations in oligodendroglial tumors (OR = 26.3; 95% CI 2.5-250.2) and inverse association in primary glioblastomas (OR = 0.13; 95% CI 0.03-0.58).
|
25797251 |
2015 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
Patients with IDH1/2 wild-type gliomas and glioblastoma-like genomic alterations, including gain on chromosome arm 7q (+7q), loss on chromosome arm 10q (-10q), TERT promoter mutation and oncogene amplification, displayed the worst outcome.
|
25783747 |
2015 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
Multiple cancer types, including up to 83% of glioblastomas (GBMs), harbor highly recurrent TERT promoter mutations of unknown function but specific to two nucleotide positions.
|
25977370 |
2015 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas.
|
25140036 |
2015 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
Interleukin-6 (IL-6) expression regulated by TERT promoter status and polymorphism, what leads us to think that TERT and IL-6 plays a significant role in GBM, where specific SNPs increase the risk of developing GBM while the rs2853669 SNP and specific mutations in the TERT promoter of the tumor lead to shorter survival.
|
26143636 |
2015 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutations were highly frequent in glioblastoma (83.9%), urothelial carcinoma (64.5%), oligodendroglioma (70.0%), medulloblastoma (33.3%) and hepatocellular carcinoma (31.4%).
|
25843513 |
2015 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
Seventy-three percent of GBM patients harbored TERT promoter mutations associated with enhanced telomerase activity and TERT mRNA expression but reduced telomere lengths (P < .001 for all).
|
25681309 |
2015 |
|
LOC110806263
|
Glioblastoma
|
0.100 |
GeneticVariation |
BEFREE |
Patients whose Grade III-IV gliomas exhibit TERT promoter mutations alone predominately have primary GBMs associated with poor median OS (11.5 months).
|
24722048 |
2014 |